Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MICAD: JNJ-40346527 in Mild Cognitive Impairment
NCT04121208Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of edicotinib in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by University of Oxford. Primary endpoint: Placebo-controlled change from baseline in cerebrospinal fluid protein marker concentration levels at 14 days. Started Apr 2021; status: terminated.
02
Drugs
edicotinib
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04121208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121208.